Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas

Diagnostic Pathology

Volumn 5, Issue 1, 2010, Pages

  Gulati, Sasha ^a,b   Ytterhus, Borgny ^b   Granli, Unn S ^b   Gulati, Michel ^b   Lydersen, Stian ^b   Torp, Sverre H ^a,b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BIOPSY; BRAIN TUMOR; CANCER INVASION; CHEMISTRY; FEASIBILITY STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; UPREGULATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ASTROCYTOMA; BIOPSY; FEASIBILITY STUDIES; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SUPRATENTORIAL NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 79956303763     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-5-18     Document Type: Article

References (62)

1. Stupp R, Reni M, Gatta G, Mazza E, Vecht C. Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol 2007, 63:72-80.
2. Chang SM, Parney IF, Huang W, Anderson FA, Asher AL, Bernstein M, Lillehei KO, Brem H, Berger MS, Laws ER, . Glioma Outcomes Project I Patterns of care for adults with newly diagnosed malignant glioma. JAMA 2005, 293:557-564. Glioma Outcomes Project I.
3. Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol 2003, 30:10-14.
4. Bazley LA, Gullick WJ. The epidermal growth factor receptor family. Endocr Relat Cancer 2005, 12(Suppl 1):S17-27.
5. Hamel W, Westphal M. Growth factors in gliomas revisited. Acta Neurochir (Wien) 2000, 142:113-137. discussion 137-118.
6. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001, 8:83-96.
7. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211-225.
8. Torp SH, Gulati S, Johannessen E, Dalen A. Coexpression of c-erbB 1-4 receptor proteins in human glioblastomas. An immunohistochemical study. J Exp Clin Cancer Res 2007, 26:353-359.
9. Weiner HL. The role of growth factor receptors in central nervous system development and neoplasia. Neurosurgery 1995, 37:179-193. discussion 193-174.
10. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002, 110:669-672.
11. Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 2006, 32:74-89.
12. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002, 94:1593-1611.
13. Mischel PS, Cloughesy TF. Targeted molecular therapy of GBM. Brain Pathol 2003, 13:52-61.
14. Contessa JN, Hamstra DA. Revoking the privilege: targeting HER2 in the central nervous system. Mol Pharmacol 2008, 73:271-273.
15. Voelzke WR, Petty WJ, Lesser GJ. Targeting the epidermal growth factor receptor in high-grade astrocytomas. Curr Treat Options Oncol 2008, 9:23-31.
16. Emanuel SL, Hughes TV, Adams M, Rugg CA, Fuentes-Pesquera A, Connolly PJ, Pandey N, Moreno-Mazza S, Butler J, Borowski V, et al. Cellular and in vivo activity of JNJ-2887 a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors. Mol Pharmacol 1063, 73:338-348.
17. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985, 313:144-147.
18. Liu L, Ichimura K, Pettersson EH, Collins VP. Chromosome 7 rearrangements in glioblastomas; loci adjacent to EGFR are independently amplified. J Neuropathol Exp Neurol 1998, 57:1138-1145.
19. Sauter G, Maeda T, Waldman FM, Davis RL, Feuerstein BG. Patterns of epidermal growth factor receptor amplification in malignant gliomas. Am J Pathol 1996, 148:1047-1053.
20. Schlegel J, Merdes A, Stumm G, Albert FK, Forsting M, Hynes N, Kiessling M. Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer 1994, 56:72-77.
21. Schlegel J, Stumm G, Brandle K, Merdes A, Mechtersheimer G, Hynes NE, Kiessling M. Amplification and differential expression of members of the erbB-gene family in human glioblastoma. J Neurooncol 1994, 22:201-207.
22. Schober R, Bilzer T, Waha A, Reifenberger G, Wechsler W, von Deimling A, Wiestler OD, Westphal M, Kemshead JT, Vega F, et al. The epidermal growth factor receptor in glioblastoma: genomic amplification, protein expression, and patient survival data in a therapeutic trial. Clin Neuropathol 1995, 14:169-174.
23. von Deimling A, Louis DN, von Ammon K, Petersen I, Hoell T, Chung RY, Martuza RL, Schoenfeld DA, Yasargil MG, Wiestler OD, et al. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg 1992, 77:295-301.
24. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 1987, 84:6899-6903.
25. Barker FG, Simmons ML, Chang SM, Prados MD, Larson DA, Sneed PK, Wara WM, Berger MS, Chen P, Israel MA, Aldape KD. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001, 51:410-418.
26. Krishnan S, Rao RD, James CD, Sarkaria JN. Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas. Front Biosci 2003, 8:e1-13.
27. Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, James CD. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 2004, 63:700-707.
28. Guillaudeau A, Durand K, Pommepuy I, Robert S, Chaunavel A, Lacorre S, DeArmas R, Bourtoumieux S, El Demery M, Moreau JJ, Labrousse F. Determination of EGFR status in gliomas: usefulness of immunohistochemistry and fluorescent in situ hybridization. Appl Immunohistochem Mol Morphol 2009, 17:220-226.
29. Torp SH, Bringedal K, Dalen A. Immunohistochemical detection of epidermal growth factor receptor in human high-grade astrocytomas--a comparison between frozen- and paraffin sections. J Exp Clin Cancer Res 2005, 24:89-92.
30. Gulati S, Berntsen EM, Solheim O, Kvistad KA, Haberg A, Selbekk T, Torp SH, Unsgaard G. Surgical resection of high-grade gliomas in eloquent regions guided by blood oxygenation level dependent functional magnetic resonance imaging, diffusion tensor tractography, and intraoperative navigated 3D ultrasound. Minim Invasive Neurosurg 2009, 52:17-24.
31. Layfield LJ, Willmore C, Tripp S, Jones C, Jensen RL. Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors. Appl Immunohistochem Mol Morphol 2006, 14:91-96.
32. Marquez A, Wu R, Zhao J, Tao J, Shi Z. Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagn Mol Pathol 2004, 13:1-8.
33. Reifenberger G, Prior R, Deckert M, Wechsler W. Epidermal growth factor receptor expression and growth fraction in human tumours of the nervous system. Virchows Arch A Pathol Anat Histopathol 1989, 414:147-155.
34. Torp SH, Helseth E, Dalen A, Unsgaard G. Epidermal growth factor receptor expression in human gliomas. Cancer Immunol Immunother 1991, 33:61-64.
35. Perez-Torres M, Valle BL, Maihle NJ, Negron-Vega L, Nieves-Alicea R, Cora EM. Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells. Exp Cell Res 2008, 314:2907-2918.
36. Zabrecky JR, Lam T, McKenzie SJ, Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 1991, 266:1716-1720.
37. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991, 51:2164-2172.
38. Hurtt MR, Moossy J, Donovan-Peluso M, Locker J. Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J Neuropathol Exp Neurol 1992, 51:84-90.
39. Jarvela S, Helin H, Haapasalo J, Jarvela T, Junttila TT, Elenius K, Tanner M, Haapasalo H, Isola J. Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival. Neuropathol Appl Neurobiol 2006, 32:441-450.
40. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001, 93:1246-1256.
41. Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bigner DD, Sampson JH. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 2009, 19:713-723.
42. Bouvier-Labit C, Chinot O, Ochi C, Gambarelli D, Dufour H, Figarella-Branger D. Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol Appl Neurobiol 1998, 24:381-388.
43. Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, Hayes RL, Miller DC. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol 1998, 8:655-667.
44. Olson JJ, Barnett D, Yang J, Assietti R, Cotsonis G, James CD. Gene amplification as a prognostic factor in primary brain tumors. Clin Cancer Res 1998, 4:215-222.
45. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003, 63:6962-6970.
46. Torp SH, Helseth E, Dalen A, Unsgaard G. Relationships between Ki-67 labelling index, amplification of the epidermal growth factor receptor gene, and prognosis in human glioblastomas. Acta Neurochir (Wien) 1992, 117:182-186.
47. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101:736-750.
48. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997, 16:1647-1655.
49. Haapasalo H, Hyytinen E, Sallinen P, Helin H, Kallioniemi OP, Isola J. c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. Br J Cancer 1996, 73:620-623.
50. Haynik DM, Roma AA, Prayson RA. HER-2/neu expression in glioblastoma multiforme. Appl Immunohistochem Mol Morphol 2007, 15:56-58.
51. Mineo JF, Bordron A, Baroncini M, Maurage CA, Ramirez C, Siminski RM, Berthou C, Dam Hieu P. Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. J Neurooncol 2007, 85:281-287.
52. Potti A, Forseen SE, Koka VK, Pervez H, Koch M, Fraiman G, Mehdi SA, Levitt R. Determination of HER-2/neu overexpression and clinical predictors of survival in a cohort of 347 patients with primary malignant brain tumors. Cancer Invest 2004, 22:537-544.
53. Schwechheimer K, Laufle RM, Schmahl W, Knodlseder M, Fischer H, Hofler H. Expression of neu/c-erbB-2 in human brain tumors. Hum Pathol 1994, 25:772-780.
54. Andersson U, Guo D, Malmer B, Bergenheim AT, Brannstrom T, Hedman H, Henriksson R. Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol 2004, 108:135-142.
55. Torp SH, Helseth E, Unsgaard G, Dalen A. C-erbB-2/HER-2 protein in human intracranial tumours. Eur J Cancer 1993, 29A:1604-1606.
56. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 1997, 57:3272-3280.
57. Koka V, Potti A, Forseen SE, Pervez H, Fraiman GN, Koch M, Levitt R. Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme. Am J Clin Oncol 2003, 26:332-335.
58. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
59. Srinivasan R, Poulsom R, Hurst HC, Gullick WJ. Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol 1998, 185:236-245.
60. Westphal M, Meima L, Szonyi E, Lofgren J, Meissner H, Hamel W, Nikolics K, Sliwkowski MX. Heregulins and the ErbB-2/3/4 receptors in gliomas. J Neurooncol 1997, 35:335-346.
61. Stern DF. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:215-223.
62. Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi OP, Elenius K. Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:259-268.